SYNCONA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123.4 GBX | -0.48% |
|
+1.98% | 0.00% |
| Apr. 11 | Syncona agrees to sell stake in investee company for GBP7.4 million | AN |
| Apr. 11 | Syncona to Sell Stake in Portfolio Company to Century Therapeutics | MT |
| Sales 2022 | 18.69M 23.25M | Sales 2023 | -39.79M -49.48M | Capitalization | 992M 1.23B |
|---|---|---|---|---|---|
| Net income 2022 | 8M 9.95M | Net income 2023 | -56M -69.64M | EV / Sales 2022 | 57.1 x |
| Net cash position 2022 | 276K 343K | Net cash position 2023 | 11K 13.68K | EV / Sales 2023 | -24.9 x |
| P/E ratio 2022 |
122
x | P/E ratio 2023 |
-17.7
x | Employees | 1,208 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syncona Limited
More press releases
| 1 day | -0.48% | ||
| 1 week | +1.98% | ||
| Current month | +0.33% | ||
| 1 month | -4.49% | ||
| 3 months | +2.66% | ||
| 6 months | -1.44% |
1 week
120.00
124.20
1 month
116.00131.60
Current year
112.80131.94
1 year
105.00162.20
3 years
105.00248.50
5 years
105.00280.00
10 years
105.00306.50
| Managers | Title | Age | Since |
|---|---|---|---|
Annabel Clark
IRC | Investor Relations Contact | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 22-01-31 | |
Virginia Holmes
BRD | Director/Board Member | 64 | 20-12-31 |
Kemal Malik
BRD | Director/Board Member | 61 | 20-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 123.4 | -0.48% | 157,297 |
| 24-04-17 | 124 | +1.64% | 263,870 |
| 24-04-16 | 122 | -0.16% | 723,060 |
| 24-04-15 | 122.2 | +0.49% | 497,008 |
| 24-04-12 | 121.6 | +0.50% | 393,235 |
Delayed Quote London S.E., April 18, 2024 at 11:35 am EDT
More quotes
Syncona Limited is a Guernsey-based closed-ended investment company. The Companyâs investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.
Sector
Investment Holding Companies
Calendar
2024-06-20
- Q4 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.234
GBP
Average target price
2.453
GBP
Spread / Average Target
+98.81%
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 1.01B | |
| +12.70% | 72.9B | |
| +51.20% | 16.93B | |
| +5.76% | 16.09B | |
| +9.15% | 14.02B | |
| -1.13% | 12.17B | |
| +10.37% | 12.03B | |
| +3.17% | 10.52B | |
| -1.92% | 9.49B | |
| +29.10% | 9.49B |
- Stock Market
- Equities
- BACT Stock
